Drug-controlled CAR T cells through the regulation of cell–cell interactions
Open Access
- 19 February 2026
- journal article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (10) , 1654-1665
Abstract
Chimeric antigen receptor (CAR) T cell therapy is constrained by on-target, off-tumor toxicities and cellular exhaustion because of chronic antigen exposure. CARs incorporating small-molecule controlled on- and off-switches can enhance both safety and therapeutic efficacy but their design is limited by the scarcity of nonimmunogenic protein elements responsive to nonimmunosuppressive, clinically approved drugs with favorable pharmacodynamics. Here we combine rational design and library-based optimization of a protein–protein interaction (PPI) of human origin to develop venetoclax-controlled drug-regulated off-switch PPI (DROP)-CARs. DROP-CARs enable dose-dependent release of the tumor-targeting scFv and consequent reduction in T cell binding to the tumor cell. Additionally, we present proof of concept for a dual DROP-CAR controlled by different small molecules, as well as for logic-gated synthetic receptors enabling STAT3 signaling. We demonstrate in vitro and in vivo function of DROP-CAR T cells and conclude that the approach holds promise for clinical application.Keywords
All Related Versions
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
This publication has 57 references indexed in Scilit:
- An In Vitro Model to Assess CRS Potential of CAR T Cells Using a Tumor Cell Line and Autologous MonocytesCurrent Protocols, 2023
- High-performance multiplex drug-gated CAR circuitsCancer Cell, 2022
- Enhanced safety and efficacy of protease-regulated CAR-T cell receptorsCell, 2022
- An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activityCell Chemical Biology, 2021
- All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapyCurrent Opinion in Biotechnology, 2020
- Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor EfficacyImmunity, 2020
- The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cellsImmunology Letters, 2019
- Safety and Tolerability of Adoptive Cell Therapy in CancerDrug Safety, 2019
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell ResponsesCell, 2018
- Venetoclax: First Global ApprovalDrugs, 2016